53 completed, 9 unknown, 6 terminated, 2 not yet recruiting. 31 Phase 2, 27 Phase 3, 17 Phase 1, 5 Phase 4.
Follow Drugs for Neglected Diseases: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR). LXE408, Miltefosine 50 MG Oral Capsule [Impavido], Placebo to LXE408 - Localized Cutaneous Leishmaniasis | Phase 2 | Not yet recruiting | Drugs for Neglected Diseases | 250 | 2026-06-15 | 2026-05-05 |
| Mycetoma Retrospective Data Collection A diagnosis of mycetoma in a medical, radiologic, or laboratory record. - Mycetoma | Unknown | Drugs for Neglected Diseases | 1600 | 2024-06-20 | 2024-08-01 | |
| Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT) Treatment of seropositive individuals (positive serology test, but parasitology not confirmed) - Human African Trypanosomiasis | Phase 3 | Not yet recruiting | Drugs for Neglected Diseases | 2500 | 2024-04-08 | 2024-04-10 |
| LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study LXE408, sodium stibogluconate, Paromomycin - Primary Visceral Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 52 | 2024-03-29 | 2025-12-18 |
| Stop Transmission of Gambiense Human African Trypanosomiasis Acoziborole - Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense | Phase 3 | Recruiting | Institute of Tropical Medicine, Belgium | 2500 | 2024-03-15 | 2026-08-27 |
| Screen and Treat Implementation for HAT Control Screen&treat - Sleeping Sickness, Trypanosomiasis, African | Withdrawn | Institute of Tropical Medicine, Belgium | 2024-01-01 | 2024-02-02 | ||
| DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan Acoziborole, Midazolam, Dextromethorphan - Trypanosomiasis, African | Phase 1 | Completed | Drugs for Neglected Diseases | 20 | 2023-02-09 | 2023-07-17 |
| Eumycetoma Long-term Post-Treatment Follow-Up Study Clinical diagnosis of recurrence - Eumycetoma | Terminated | Drugs for Neglected Diseases | 51 | 2023-01-26 | 2024-07-23 | |
| A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis LXE408, Placebo, AmBisome® - Primary Visceral Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 101 | 2022-12-27 | 2026-04-30 |
| Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients Acoziborole - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 35 | 2022-07-09 | 2026-04-06 |
| Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan Leishmaniasis, Leishmaniasis, Visceral | Completed | Epicentre | 52 | 2022-05-31 | 2025-04-24 | |
| PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets Oxfendazole, Placebo - Filariasis | Phase 1 | Completed | Swiss Tropical & Public Health Institute | 30 | 2022-04-21 | 2022-12-20 |
| Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects Acoziborole, Placebo - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 1208 | 2021-12-30 | 2025-03-20 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease Short regimen of benznidazole, Short treatment with benznidazole, Standard treatment with benznidazole - Chagas Disease | Phase 3 | Recruiting | Laboratorio Elea Phoenix S.A. | 300 | 2021-07-28 | 2023-11-30 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World Meglumine Antimoniate, Miltefosine, Thermotherapy machine - Cutaneous Leishmaniases | Phase 3 | Completed | Drugs for Neglected Diseases | 184 | 2021-01-26 | 2025-05-08 |
| ADME Study of Acoziborole in Healthy Subjects [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C - Trypanosomiases, African | Phase 1 | Completed | Drugs for Neglected Diseases | 6 | 2020-02-05 | 2021-04-27 |
| New Therapies and Biomarkers for Chagas Infection Benznidazole, Nifurtimox - Trypanosoma Cruzi Infection, Chagas Disease | Phase 2 | Completed | University of Texas, El Paso | 450 | 2019-12-18 | 2024-07-17 |
| Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense Fexinidazole - Trypanosomiasis, African, Sleeping Sickness | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 45 | 2019-09-29 | 2025-01-30 |
Showing 20 of 73. Sign in to see all of them.
Leishmaniasis, Visceral (15) · Trypanosomiasis, African (14) · Chagas Disease (10) · Neglected Diseases (6) · Filariasis (5) · Leishmaniasis, Cutaneous (5) · Parasitic Diseases (5) · Onchocerciasis (4) · Infections (3) · Mycetoma (3) · Trypanosomiasis (3) · Acquired Immunodeficiency Syndrome (2) · Bronchiolitis Obliterans Syndrome (2) · Extensively Drug-Resistant Tuberculosis (2) · Helminthiasis (2)
fexinidazole (12) · miltefosine (11) · liposomal amphotericin B (9) · Paromomycin (7) · benzonidazole (7) · Antimony Sodium Gluconate (4) · Bay 44-4400 (4) · Nifurtimox (4) · Eflornithine (3) · LXE408 (3) · amphotericin B, deoxycholate drug combination (3) · emodepside (3) · Clofazimine (2) · Linezolid (2) · Meglumine Antimoniate (2)
Democratic Republic of the Congo (11) · Kenya (8) · Sudan (8) · Ethiopia (7) · Uganda (7) · Bolivia (6) · France (5) · India (5) · United Kingdom (5) · Argentina (4) · Brazil (4) · Guinea (4) · South Africa (4) · Malaysia (3) · Peru (3)
Antoine Tarral, MD (3) · Lionel Hovsepian, MD (3) · Faustino Torrico, PhD (2) · Isabela Ribeiro, MD (2) · Isabelle Andrieux-Meyer, MD (2) · Ivan Dario Velez, Prof (2) · Adellina R Riarte, MD (1) · Ahmed Fahal, Prof (1) · Ahmed M Musa, MD PhD (1) · Ahmed M Musa, MD, Prof (1) · Alejandro Llanos-Cuentas, MD, PhD (1) · Ana LT Rabello, MD PhD (1)
PMID 30509941, PMID 16235350, PMID 16702588, PMID 19559476, PMID 19636365, PMID 21049063, PMID 21255828, PMID 21264349, PMID 21375777, PMID 21718522, PMID 22724029, PMID 23209861, PMID 24454970, PMID 24867876, PMID 26573827, PMID 27627654, PMID 28558062, PMID 28662034, PMID 29020217, PMID 29113731, PMID 29352704, PMID 30044792, PMID 30102705, PMID 30188978, PMID 30529029, PMID 30653490, PMID 30789910, PMID 31986140, PMID 32071055, PMID 32171422, PMID 33836161, PMID 33855449, PMID 33865507, PMID 34143998, PMID 34489274, PMID 34748572, PMID 34972765, PMID 35078765, PMID 35107141, PMID 35255096, PMID 35698158, PMID 35925555, PMID 36164254, PMID 36179736, PMID 36409773, PMID 36460027, PMID 36546625, PMID 36763327, PMID 36968554, PMID 37256863
2017 (2), 2015 (1), 2016 (1), 2018 (1), U01AI129783 (1)